BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

SCYNEXIS, Inc.'s Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments


11/12/2012 9:31:23 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SCYNEXIS, Inc. announced today the results of a Phase 2a study of lead candidate SCY-635 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) for the treatment of the hepatitis C virus (HCV) that showed SCY-635 has the potential to play an important role in the reversal of immune exhaustion, restoring the immune systems of difficult to treat patients with HCV. The presentation “Short Duration Treatment with SCY-635 Restores Sensitivity to Peg-IFN/RBV in Difficult to Treat, IL28B TT/CT, HCV Genotype 1 Patients” was given by lead investigator Dr. Andrew J. Muir at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, Massachusetts. The results demonstrate that SCY-635 has the potential to open up a new frontier in immunotherapy for the treatment of HCV as a synergistic Direct Acting Antiviral (DAA) and a stimulator of the host immune system (Immune Acting Antiviral or IAA), augmenting existing treatments.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->